Omeros Corporation - Special Call Transcript
Hello, and welcome to the Omeros Corporation Conference Call. My name is Michelle, and I will be the operator for today's call. (Operator Instructions)
I will now turn the call over to Mr. Peter Cancelmo, Vice President and General Counsel. Sir, you may begin.
Good morning, and thank you for joining today to discuss data from our compassionate use study of narsoplimab in COVID-19 patients with acute respiratory distress syndrome, or ARDS. These data were announced this morning by a press release and published online by the journal, Immunobiology.
I'd like to remind you that some of the statements that will be made on today's call will be forward-looking. These forward-looking statements include, without limitations, statements regarding the efficacy, safety and intended utilization of our investigational product, our plans and expectations regarding the development of narsoplimab for the treatment of COVID-19, or COVID-19 associated ARDS, the therapeutic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |